501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Comments
on Legalization of Marijuana in Canada,
Impaired Driving and Workplace
Safety
The Cannabix Marijuana Breathalyzer is being developed to give law
enforcement and employers a tool to enforce public safety.
Vancouver, British
Columbia -- October
16,
2018 -- InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC PINK: BLOZF) (the "Company or
Cannabix") developer of the Cannabix Marijuana Breathalyzer for law
enforcement and the
workplace provides the
following statement related to the legalization of marijuana for
recreational use across Canada: "The introduction of legalized
marijuana use in Canada is a watershed moment as it relates
to public
safety on our
roads
and workplaces. Cannabix applauds
the significant
efforts that
are
underway by the Government
of Canada and others to increase public
awareness of the dangers of drugged driving on
our
roadways and the acute problems of being under the
influence of drugs
in the
workplace. A
recent survey
by
the
Angus Reid Institute (dated
September
25, 2018)
finds
a
majority of Canadians lack
confidence in the ability of their community police to assess and
punish those driving under the influence of marijuana.
Furthermore,
according to MADD Canada, drugs are present in
fatal crashes nearly twice as often as alcohol and that
Canada's existing
system does a very poor job of detecting drivers under the
influence of drugs (news
release May 29, 2018).
The
Human
Resources Professionals Association in January 2018,
conducted a survey in
Ontario
and
found
that 71 per cent of its
members do not feel
prepared for legalization, with almost 48 per cent citing concerns
about ensuring a safe workplace.
As the
issue of drugged driving and influence of
drugs in the workplace becomes
increasingly acute, Cannabix is using its technology,
research and
development (R&D) and scientific
experience to develop
effective tools to
aid law enforcement and help governments and the public transition
to marijuana legalization in various jurisdictions.
Cannabix
Technologies has
been on the forefront in R&D
to
create an accurate breath
test for 9-tetrahydrocannabinol
- the
psychoactive component of marijuana that causes impairment.
We
believe that establishing
point-of-care breath
testing technology
for
cannabis is the
future
for law enforcement and workplace testing, as it is
non-invasive,
will be
easy to use,
and
will look to provide superior sensitivity to help
better
determine impairment. Cannabix is a well
funded Canadian company that is rapidly developing marijuana
breathalyzer technology.
Cannabix has been
building upon its promising characterization
results
from August and with a secondary bench version device to establish
repeatable results in multiple devices. Thus far
testing
has demonstrated the
ability to isolate 9-tetrahydrocannabinol
("THC") and suppress
background substrates
and
scientists are continuously
working to improve
resolving power.
Cannabix is
developing an innovative FAIMS (field asymmetric
waveform ion mobility spectrometry) based instrument for the
detection of THC.
FAIMS
works as an "ion blocking" technology, essentially blocking
unwanted ions/analytes and allowing specified ions to pass through
for detection. The
characterization work has
been conducted using
a bench version of
the FAIMS device. Cannabix
scientists
have
been actively tuning the FAIMS device coupled to real
time switchable mass spectrometry to
detect
key molecules and their complex pathways in the body to enable the
identification of recency of use.
The
Company also reports that it has short listed 2 potential medical
device development companies in order to develop the next version
of the device as well as create multiple devices, that would be
used for pilot testing.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage,
days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment
by THC
can be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.